Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

被引：1
|
作者：
Venugopal, Sangeetha [1 ]
Kadia, Tapan M. [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Daver, Naval [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Garcia-Manero, Guillermo [1 ]
Montalban-Bravo, Guillermo [1 ]
Maiti, Abhishek [1 ]
Yilmaz, Musa [1 ]
Issa, Ghayas C. [1 ]
Chien, Kelly S. [1 ]
Pierce, Sherry A. [1 ]
Kantarjian, Hagop [1 ]
Short, Nicholas J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
794
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine
    Luebbert, Michael
    Schmoor, Claudia
    Hagemeijer, Anne
    Hackanson, Bjoern
    Claus, Rainer
    Rueter, Bjoern
    Schmid, Mathias
    Germing, Ulrich
    Kuendgen, Andrea
    Rethwisch, Volker
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Heil, Gerhard
    Wijermans, Pierre W.
    Doehner, Konstanze
    Doehner, Hartmut
    BLOOD, 2011, 118 (21) : 1119 - 1120
  • [22] Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML
    Rautenberg, Christina
    Stepanow, Stefanie
    Lauseker, Michael
    Germing, Ulrich
    Jaeger, Paul
    Geyh, Stefanie
    Schuler, Esther
    Koehrer, Karl
    Gattermann, Norbert
    Haas, Rainer
    Kobbe, Guido
    Schroeder, Thomas
    BLOOD, 2019, 134
  • [23] Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy
    Subari, Salih
    Baidoun, Firas
    Hreh, Muhanad
    Patnaik, Mrinal
    Hashmi, Shahrukh
    Elliott, Michelle
    Hogan, William
    Litzow, Mark
    Al-Kali, Aref
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (04) : 409 - 415
  • [24] Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy
    Salih Subari
    Firas Baidoun
    Muhanad Hreh
    Mrinal Patnaik
    Shahrukh Hashmi
    Michelle Elliott
    William Hogan
    Mark Litzow
    Aref Al-Kali
    International Journal of Hematology, 2016, 103 : 409 - 415
  • [25] Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia
    Connor, Panelmatthew P.
    Prathapa, Neeharika
    Frey, Noelle V.
    Gill, Saar
    Hexner, Elizabeth O.
    Bruno, Ximena Jordan
    Lai, Catherine
    Loren, Alison W.
    Luger, Selina M.
    Matthews, Andrew H.
    McCurdy, Shannon R.
    Perl, Alexander
    Porter, David L.
    Zeringue, Arlene
    Oved, Joseph H.
    Olson, Timothy S.
    Pratz, Keith W.
    Babushok, Daria V.
    BLOOD, 2023, 142
  • [26] Comparison between Upfront Transplantation and Pretransplant Cytoreductive Treatment in Patients with MDS and secondary AML - a single center analysis of 165 consecutive patients
    Schroeder, Thomas
    Wegener, Nadija
    Lauseker, Michael
    Rautenberg, Christina
    Nachtkamp, Kathrin
    Schuler, Esther
    Kondakci, Mustafa
    Haas, Rainer
    Germing, Ulrich
    Kobbe, Guido
    BONE MARROW TRANSPLANTATION, 2018, 53 : 116 - 117
  • [27] Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study
    Zhang, Jian
    Song, Baoquan
    Liu, Yin
    Wu, De-Pei
    Qiu, Huiying
    BLOOD, 2023, 142
  • [28] Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
    Hammond, Danielle
    Loghavi, Sanam
    Wang, Sa A.
    Konopleva, Marina Y.
    Kadia, Tapan M.
    Daver, Naval G.
    Ohanian, Maro
    Issa, Ghayas C.
    Alvarado, Yesid
    Short, Nicholas J.
    Sasaki, Koji
    Pemmaraju, Naveen
    Montalban-Bravo, Guillermo
    Lachowiez, Curtis A.
    Maiti, Abhishek
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Pierce, Sherry R.
    Kantarjian, Hagop M.
    Dinardo, Courtney D.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [29] Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial
    Phinyo, Phichayut
    Patumanond, Jayanton
    Pongudom, Saranya
    BMC RESEARCH NOTES, 2021, 14 (01)
  • [30] Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial
    Phichayut Phinyo
    Jayanton Patumanond
    Saranya Pongudom
    BMC Research Notes, 14
12345